In recent years, the fight against cancer has seen significant advances, particularly with the emergence of targeted therapy. Among the most promising strategies in this domain is the development of radioactive drug conjugates(RDCs). These innovative therapeutic agents combine the targeting capabilities of antibodies with the cytotoxic effects of radioactive isotopes, providing a powerful...
Alfa Cytology has officially released its antibody-drug conjugates(ADCs) development services which demonstrates the dedication to fighting cancer through advanced treatment methods.
Alfa Cytology, which stands at the forefront of oncology service provision in New York United States, has announced its sophisticated antibody-drug conjugates(ADCs) development...
In the ever-evolving landscape of cancer research, two intriguing concepts have emerged that are reshaping how scientists approach treatment: synthetic lethality and parthanatos. Both concepts encapsulate the complexity of cellular processes and open new avenues for targeted therapies.
What is Synthetic Lethality?
Synthetic lethality occurs when the...
Alfa Cytology unveils advanced PD-1 inhibitor development service for cancer research.
Alfa Cytology, a prominent service provider in the oncology landscape, has recently launched its innovative PD-1 inhibitor development services. This initiative marks a significant advancement in the quest for more effective cancer therapies, focusing on enhancing precision...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek